Clinical trial · Other
A Study of CT-388 in Participants With Obesity or Overweight
Roche-CT388-Ph1
Trial identity
- Registry
- Other
- Registry ID
- Roche-CT388-Ph1
- Phase
- Phase 1
- Design
- Interventional
- Allocation
- Randomized
- Masking
- Double-blind
- Overall status
- Recruiting
- Result status
- none
Sponsors & collaborators
- Sponsor
- Roche
- Collaborators
- —
Intervention assets
Arms
| Arm | Intervention | Enrollment |
|---|---|---|
| CT-388 | CT-388 subcutaneous once weekly | — |
| Placebo | placebo subcutaneous | — |
Population & enrollment
- Population summary
- Adults with obesity or overweight.
- Eligibility summary
- BMI ≥30 or ≥27 with comorbidity.
- Planned enrollment
- 80
- Actual enrollment
- 80
Endpoints
- Primary endpoints
Safety and tolerability
Pharmacokinetics
- Secondary endpoints
Body weight change
Pharmacodynamics
Dates
- Start date
- Jan 15, 2024
- Primary completion
- Dec 1, 2024
- Completion date
- Mar 1, 2025
- Last synced
- Aug 15, 2024
Locations
- United States
Changes
- CT-388 acquired by Roche via Carmot Therapeutics acquisition in December 2023.
Plain-language interpretation
A Study of CT-388 in Participants With Obesity or Overweight is a Phase 1 Interventional sponsored by Roche. It is evaluating CT-388 in Adults with obesity or overweight.. The primary endpoints are Safety and tolerability; Pharmacokinetics.
Registry disclaimer: Information is derived from public registry records and may lag behind the official source. Always verify against Other.